Award Sub-Category: Advancements in Neurological Treatments

Voranigo is a first-in-class, FDA-approved medicine used to treat adults
and children 12 years & older with Grade 2 astrocytoma or
oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or
isocitrate dehydrogenase-2 (IDH2) mutation. Voranigo offers patients the
ability to actively manage their disease with a once-daily pill.

The “BrainProbe,” developed by Professor Albert Yang, is an innovative
platform leveraging explainable deep learning and cloud-based interfaces
to assess and diagnose neuropsychiatric disorders. It enables precise
tracking of brain region degeneration over time and identifies targeted
regions for personalized brain stimulation therapies.